BioSpace News Archive

SAB Biotherapeutics today reported financial results for the third quarter ended September 30, 2022, and provided a company update.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) to enroll patients in the U.S. for its Phase 2b PARADIGM study for its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).

DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments.

Spinal Stabilization Technologies (SST) has announced the start of the LOPAIN2 clinical trial of the PerQdisc™ Nucleus Replacement Device (NRD).

The global Precision Oncology market is forecasted to grow at a rate of 9.9% from USD 49.98 billion in 2019 to USD 99.72 billion in 2030.

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) announced for its third quarter ended September 30, 2022 and that it has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022 with the Securities and Exchange Commission (“SEC”) on November 14, 2022.

The global downstream processing market is forecasted to grow at a rate of 12.7%, from USD 18.22 billion in 2019 to USD 45.49 billion in 2030.

The global bone metastasis market size was significantly robust in 2021 and is expected to register a rapid revenue CAGR over the forecast period.

According to Nova one advisor, the global Cancer Biomarkers market was valued at USD 12.4 billion in 2022 and it is expected to hit around USD 32.9 billion by 2030 with a CAGR of 19.7% during the forecast period 2022 to 2030.